Celltrion’s Omlyclo Gets EC Green Light for Allergic Conditions
The approval is supported by robust clinical evidence, including results from a global Phase III trial. Omlyclo® is the first
Read more
Immunology
Recombinant HLA Proteins
imusyn offers an unmatched portfolio of top-tier recombinant HLA class I and class II proteins, produced as truncated, soluble antigens
Read more
Peptide Binding Analysis
imusyn’s imuPep Class I Peptide Binding Analysis is designed to determine the stability of peptide/HLA class I complexes, allowing researchers
Read more
Animal Immunology and Preclinical Research Facility, Behring Campus Eystrup, Germany
The Behring Campus Eystrup is a cutting-edge research facility specialising in animal immunology, antibody development, and preclinical research. Located at
Read more
Vertex Expands Immunotherapy Capabilities with $4.9bn Alpine Acquisition
Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc., a biotechnology firm dedicated to pioneering protein-based immunotherapies, jointly announced the signing
Read more
Pfizer’s ABRYSVO® Shows Promising Results in Phase 3 Trial Targeting RSV Prevention in High-Risk Adults
Pfizer has announced encouraging findings from its ongoing pivotal Phase 3 clinical trial, known as MONeT (RSV IMmunizatiON Study for
Read more
FDA Greenlights Iovance’s AMTAGVI™ as First T-cell Therapy for Solid Tumor Cancer
Iovance Biotherapeutics, Inc., a leading biotechnology firm specialising in pioneering, developing, and delivering advanced polyclonal tumor infiltrating lymphocyte (TIL) cell
Read more
Roche’s Tecentriq SC Becomes the EU’s First Approved Subcutaneous Injection PD-(L)1 Cancer Immunotherapy
The European Commission (EC) has granted marketing authorisation for Roche’s Tecentriq® SC (atezolizumab) making it the first European Union PD-(L)1
Read more
AstraZeneca to Buy Gracell Advancing Cell Therapy Ambition
AstraZeneca announced it has agreed to acquire Gracell Biotechnologies Inc, which is set to advance its cell therapy portfolio across
Read more
Boehringer Ingelheim Strengthens Immuno-oncology Portfolio with T3 Pharma Acquisition
Boehringer Ingelheim has confirmed the acquisition of T3 Pharmaceuticals AG, a Swiss clinical-stage biotech company thereby expanding its immuno-oncology portfolio.
Read more